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Introduction
This chapter will first describe the natural function of HLA-
B27, before presenting possible mechanisms by which
HLA-B27 might be involved in disease pathogenesis. We
will review the data available from HLA-B27 transgenic
animals, from structural studies and from biochemical
analysis of HLA-B27 function. A concluding section will
identify key lines of current and future research.
Historical background
Possession of the human leukocyte antigen (HLA) class 1
allele HLA-B27 is strongly associated with development of
the spondyloarthritides, a group of related diseases
including ankylosing spondylitis and reactive arthritis (see
Table 1). Ankylosing spondylitis is a common inflammatory
rheumatic disease, affecting up to 0.5% of the population.
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Chapter summary
The human leukocyte antigen HLA-B27 is strongly associated with development of a group of
inflammatory arthritides collectively known as the spondyloarthritides. We have set out to define the
natural immunological function of HLA-B27, and then to apply this knowledge to understand its
pathogenic role. Human leukocyte antigen class 1 molecules bind antigenic peptides for cell surface
presentation to cytotoxic T lymphocytes. HLA-B27 binds and presents peptides from influenza, HIV,
Epstein–Barr virus, and other viruses. This leads to vigorous and specific cytotoxic T lymphocyte
responses, which play an important role in the body’s immune response to these viruses. HLA-B27
thus carries out its natural function highly effectively. Although many theories have been proposed to
explain the role of HLA-B27 in the pathogenesis of spondyloarthropathy, we favour those postulating
that the pathogenic role of HLA-B27 stems from its natural function. For example, the ‘arthritogenic’
peptide hypothesis suggests that disease results from the ability of HLA-B27 to bind a unique peptide
or a set of antigenic peptides. Additionally, a number of lines of evidence from our laboratory and other
laboratories have suggested that HLA-B27 has unusual cell biology. We have recently demonstrated
that HLA-B27 is capable of forming disulfide-bonded homodimers. These homodimers are expressed
on the cell surface and are ligands for a number of natural killer and related immunoreceptors,
expressed on a variety of cell types including natural killer cells, T lymphocytes and B lymphocytes, and
members of the monocyte/macrophage lineage. We are currently investigating the possibility that such
interactions could be involved in disease pathogenesis.
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was first described in 1973 [1], and is among the
strongest described for a HLA locus. A recent study found
that 94% of ankylosing spondylitis patients are HLA-B27-
positive, compared with 9.4% of controls, giving an odds
ratio of 161 with a 95% confidence interval of 113–230
[2]. HLA-B27 is also less significantly associated with
reactive arthritis [3] and with the spondyloarthritis associ-
ated with psoriasis and inflammatory bowel disease [4].
These conditions share clinical features including arthritis
of the spine and large joints, and involvement of the skin,
eye, genital mucosa and heart.
While the pathogenic role of HLA-B27 in the spondylo-
arthropathies is unknown, numerous theories have been
proposed. These theories are reviewed in [5], and many are
applicable to the HLA associations with other autoimmune
diseases (reviewed in [6]). Some theories suggest that the
pathogenic role of HLA-B27 is independent of its immune
function; for example, suggesting that HLA-B27 acts as a
receptor for a disease-causing microorganism or is even
merely a genetic marker for the true gene responsible. We
favour theories suggesting that the pathogenic role of HLA-
B27 stems from its immunological role. The ‘arthritogenic’
peptide theory (see later) proposes that HLA acts to
present antigens to T cells. Alternatively, it is possible that
HLA-B27 itself acts as a source of antigen, providing pep-
tides that can be presented by other HLA molecules.
The finding that the natural role of HLA molecules is
peptide binding and presentation to T cells [7,8] led to the
suggestion that the spondyloarthropathies result from the
ability of HLA-B27 to bind a unique set of peptides [9].
This ‘arthritogenic’ peptide hypothesis proposes that
disease results from an HLA-B27-restricted cytotoxic T-cell
response to a peptide or peptides found only in joint and
other affected tissues. Such a peptide could be bound and
presented by all disease-associated HLA-B27 subtypes
(see later), but not by other class I molecules. Pathogenic T
cells might be primed in the joint or at other sites such as
the genital or gut mucosa. A modification of this original
hypothesis could entail a breakdown of self-tolerance by
initial HLA-B27-restricted presentation of a peptide or pep-
tides derived from one of the triggering pathogens.
If the disease association of HLA-B27 is indeed a conse-
quence of its physiological role in peptide presentation,
HLA-B27-restricted cytotoxic T lymphocytes (CTL), spe-
cific for self-epitopes or bacterial epitopes, should be
demonstrable in the involved joints of patients with
spondyloarthropathies. Although Yersinia-specific and Sal-
monella-specific clones have been isolated from two
patients with reactive arthritis [10], many groups have
found predominant CD4 T-cell responses to triggering
bacteria within the joint.
Although an arthritogenic peptide model of disease causa-
tion is supported by the epidemiological and functional
studies of HLA-B27 subtypes (see later), evidence from
patients and from transgenic models (see later) suggests
that other factors and mechanisms need to be considered.
Animal models of HLA-B27-associated disease
Rats and mice carrying HLA-B27 as a transgene provide
strong evidence that HLA-B27 is directly involved in
disease pathogenesis. These animals can develop ill-
nesses similar to the spondyloarthropathies. Rats carrying
a high copy number of HLA-B*2705 transgenes develop
an illness characterized by peripheral and axial arthritis,
gut inflammation, and genital and skin lesions [11]. Inter-
estingly, rats kept in germ-free conditions do not develop
the inflammatory intestinal or peripheral joint disease [12].
It appears that this disease can be transferred by foetal
liver cells alone, suggesting that antigen presentation by
HLA-B27 in peripheral tissues such as joints is not essen-
tial for development of disease [13].
Mice transgenic for HLA-B27 do not normally develop
disease. However, spontaneous inflammatory arthritis
develops in mice transgenic for HLA-B27 but lacking
murine beta-2-microglobulin (β2m), following transfer from
germ-free to conventional conditions [14]. In the absence
β2m, these animals express very low levels of class 1 mol-
ecules. Although normally conformed HLA-B27 is not
expressed in these mice, HLA-B27 heavy chains (not
associated with β2m) can be detected on the cell surface
of concanavalin A-treated peripheral blood leukocytes
using the monoclonal antibody HC10 [15].
HLA-B27 structure and function
Much is now known of the molecular structure, peptide-
binding specificity and cell biology of HLA-B27. Solution
of the crystal structure of HLA-B27, crystallized with a
mixture of self-peptides [16], showed that short peptides
Table 1
HLA-B27-associated spondyloarthritides
HLA-B27 frequency 
Disease (%) (approximate)
Ankylosing spondylitis 96
Undifferentiated spondyloarthropathy 70
Reactive arthritis 30–70
Colitis-associated spondyloarthritis 33–75
Psoriatic spondyloarthritis 40–50
Juvenile enthesitis-related arthritis 70
Iritis 50
Cardiac conduction defects with aortic  Up to 88
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are bound in an extended conformation within a peptide
binding groove. A common arginine residue was found at
the second position of all bound peptides. The long side
chain of this arginine was accommodated in the ‘B’ or ‘45’
pocket, comprising in HLA-B27 a unique combination of
residues: 45E, 67C, 34V, 26G and 24T. Amino acid
analysis of self-peptides eluted from HLA-B27 has con-
firmed the presence of this arginine residue at the second
position [17,18]. Arginine at the second position of the
bound peptide is thus an anchor residue for HLA-B27.
There are also preferences for particular amino acids at
other positions, with these preferences differing between
different HLA-B27 subtypes. HLA-B*2705 thus appears
to bind peptides with C terminal amino acids that are
either aromatic, hydrophobic or positively charged,
whereas HLA-B*2702 can probably only accommodate
aromatic or hydrophobic residues at this position [18].
Finally, measurement of the ability of different peptides to
bind to HLA-B27 has confirmed the importance of the P2
arginine (for example [19,20]), and also confirmed that dif-
ferent subtypes probably bind different but overlapping
subsets of peptides [21,22].
Molecular epidemiological studies have confirmed the asso-
ciation of HLA-B*2702, HLA-B*2704, and HLA-B*2705
with spondyloarthritis first described by Breur-Vriesendorp
et al. [23,24]. However, molecular epidemiological studies
of other subtypes have produced somewhat conflicting
results. Thus, although HLA-B*2703 and HLA-B*2706
have been reported as not associated with disease
[24,25], spondyloarthropathy patients bearing these sub-
types have subsequently been described [26]. This is an
important area of research as these subtypes differ princi-
pally in their peptide-binding specificities, and these find-
ings, if confirmed, would support arthritogenic peptide
models of pathogenesis.
The role of HLA-B27 in immune responses to
viral infection
We have shown that individuals infected with influenza A or
HIV make vigorous CTL responses to specific viral peptide
epitopes that are presented by HLA-B27 [27,28]. Evidence
that HLA-B27-restricted CTL play a major role in HIV infec-
tion has recently come from long-term studies of the viral
sequence. For certain patients, viral ‘escape’ mutants that
no longer bind to HLA-B27 accumulate after a number of
years. These patients, but not those retaining the original
viral sequence, progressed to develop AIDS [29].
Using the response to influenza nucleoprotein residues
383–391 as a model, we previously defined the rules for
peptide binding to HLA-B27, and identified the key
residues for subsequent recognition by the T-cell receptor
for antigen (TCR) of cytotoxic T cells [19]. Both healthy
and spondyloarthritis patients made good HLA-B27-
restricted CTL responses, showing that there is nothing
abnormal about the natural function of HLA-B27 in
patients with spondyloarthropathy. These findings have
also allowed us to predict which residues of a potential
arthritogenic peptide could be flexible or conserved if mol-
ecular mimicry plays a role in disease pathogenesis.
Finally, we have also shown that the TCR of CTL recogniz-
ing the HLA-B27/influenza nucleoprotein peptide combi-
nation use a highly conserved repertoire of TCRs [30].
This has lead to studies of the TCR repertoire in patients
with spondyloarthropathy, which found evidence of
expanded T-cell populations [31], of which some bear
identical or almost identical TCRBV chain sequences.
One interpretation of these findings is that these oligo-
clonal expansions are driven by a self-antigen within the
joint, presumably presented by HLA-B27 (May et al.,
unpublished data).
New developments and future prospects in
the study of peptide presentation by HLA-B27
The generation of fluorogenic multimeric major histocom-
patibility complexes (usually tetramers) has recently
proven invaluable for phenotypic analysis of viral
responses ex vivo [32]. This technique is now also being
applied to the study of autoimmune disease, and has
recently been reviewed in Arthritis Research [33]. We
have made fluorescent HLA-B27/β2m/peptide tetramers
for use in studying T-cell recognition of defined com-
plexes, such as with the influenza peptide [34].
Recent advances in genomics and bioinformatics promise
to revolutionize our investigation of autoimmune and infec-
tious diseases. For example, ‘search’ programs have been
developed that can identify potential HLA-B27-binding epi-
topes as well as those likely to be generated by the proteo-
some. These methods have now been exploited to hunt for
potential arthritogenic peptides within the genome of
Chlamydia trachomatis, one of the organisms known to
trigger reactive arthritis. Peptides have been identified and
immune responses detected in both HLA-B27 transgenic
mice and in patients with reactive arthritis (following C. tra-
chomatis infection) using both enzyme-linked immunospot
(ELISPOT) assays and tetrameric HLA-B27/β2m/peptide
complexes [35].
HLA-B27 cell biology and disease
Another distinct, but not necessarily exclusive, possibility
is that unique features of the biochemistry or cell biology
of HLA-B27 predispose to disease development. A
number of lines of evidence suggest that HLA-B27 may
not behave like most other class 1 molecules.
An early observation that cell surface HLA-B27 molecules
were peptide-receptive lead to the suggestion that
disease might result from presentation to T cells of extra-
Available online http://arthritis-research.com/content/4/S3/S153S156
cellular peptides not normally accessible to the class 1
processing pathway [36]. Unusually long peptides have
been isolated bound to HLA-B27 [37]. We have recently
shown that HLA-B27 heavy chains can form homodimers
in vitro that are dependent on disulfide bonding through
their cysteine 67 residues [38]. These homodimers do not
contain  β2m but are capable of peptide binding, and
adopt a different conformation to ‘standard’ β2m-associ-
ated HLA-B27 complexes; for example, reacting with the
monoclonal antibody HC10. These ‘HC-B27’ homodimers
can be detected at the cell surface of HLA-B27-trans-
fected cell lines, and are more abundantly expressed when
the cell’s antigen-presenting function is impaired (Bird et
al., unpublished observations).
Figure 1 shows an example of HLA-B27 heavy chain
homodimer expression in the cell line LBL721.220. A key
role for the unpaired cysteine at position 67 of the HLA-
B27 alpha 1 helix is suggested by site-directed mutagene-
sis (Bird et al., unpublished observations). Figure 2 shows
a molecular model of a HLA-B27 homodimer. A disulfide
bond is shown between position 67 of the two HLA-B27
heavy chains. It is not yet known whether HC-B27 homo-
dimer expression is specific for, or indeed correlates with,
spondyloarthropathy, or whether HLA-B27-negative
patients with spondyloarthritis express homodimers of
other HLA alleles. Interestingly, we have recently observed
HLA-B27 homodimer expression at the cell surface of
HLA-B27+/β2m knockout mice.
These and other findings have lead to two novel hypothe-
ses for disease causation. Colbert and colleagues have
proposed that homodimer formation is a symptom of
HLA-B27 ‘misfolding’ within the endoplasmic reticulum,
and that accumulation of misfolded protein results in a
potentially proinflammatory intracellular stress response
[39]. Alternatively, we have suggested that HLA-B27 heavy
chain homodimers may be expressed at the cell surface,
where they may act as a proinflammatory target or receptor
for humoral or cell-mediated autoimmune responses.
We have recently shown that tetrameric complexes of
HLA-B27 heavy chain homodimers bind to certain natural
killer (NK) and related receptors, expressed on lympho-
cytes, NK cells and cells of the monocyte/macrophage
lineage. (Kollnberger et al., unpublished data). The func-
tional outcome of the interaction of HLA-B27 with NK
receptors and other immunoreceptors is as yet unclear.
Although many killer immunoglobulin-like receptors have
inhibitory effects, there is accumulating evidence that
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Figure 1
Disulfide-bonded HLA-B27 heavy chain homodimers are present in
HLA-B*2705 transfected LBL721.220 cells. HC-10 western blot
shown under non-reducing (upper panel) and reducing (lower panel)
conditions. The left-hand lane shows untransfected 721.220 cells.
Figure 2
Hypothetical molecular model of the HLA-B27 heavy chain homodimer structure. The alpha 1, 2, and 3 domains of two HLA-B27 molecules are
shown in ribbon form, bound peptide shown. Orientation: cell surface at bottom of picture.S157
expression of certain receptors is associated with pro-
longed survival of memory T cells [40].
One possible model of disease causation is presented in
Figure 3. We first show infection of HLA-B27-expressing
cells by an organism capable of triggering spondylo-
arthropathy.  This infection results in interference of the
cellular antigen-presenting function and consequent
expression of aberrant HLA-B27 homodimers [2]. Notably,
other stresses at other sites (e.g. mucosae) could have
similar effects. Cell-surface B27 homodimers engage NK
or related immunoreceptors expressed on lymphocytes or
other cells within the joint, resulting in local cytokine pro-
duction or enhanced cellular activity [4], and hence per-
petuating joint inflammation. Since both CD8 and CD4
T cells can express NK receptors, such a hypothesis could
explain the involvement of either cells in disease patho-
genesis (expanded populations of both CD4 and CD8
T cells are found in reactive arthritis [31]).
An alternative explanation for the involvement of CD4
T cells in spondyloarthropathy has been suggested by
recent evidence from Gaston’s group showing that
HLA-B27 can itself be recognized by CD4 T cells. Different
patterns of reactivity have been identified, and it has been
suggested that empty or homodimeric forms are being rec-
ognized [41]. This is an exciting area for future study.
Concluding remarks
Work from our group and other groups has shown that
HLA-B27 appears to excel at its natural function of
binding and presenting viral peptide epitopes to cytotoxic
T cells. We have suggested that HLA-B27 may, however,
act as a ‘double-edged sword’. Thus, certain features of
its peptide binding ability or cell biology (perhaps those
favouring excellent antiviral responses) might also lead to
autoimmunity. The recent demonstration that HLA-B27
can interact with a number of different immunoreceptors
on different cell types has opened up promising new
avenues of research into clarifying its role in the pathogen-
esis of spondyloarthropathy.
Glossary of terms
β2m = beta-2-microglobulin; HC10 = a monoclonal
antibody with specificity for HLA class I heavy chains;
HC-B27 = β2m-unassociated HLA-B27 heavy chain
homodimer.
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